Hill Madison S, Cartron Alexander M, Burgoyne Mary, Driscoll Marcia S
Department of Dermatology, University of Maryland School of Medicine, Baltimore, Maryland.
Department of Obstetrics, Gynecology and Reproductive Sciences, University of Maryland School of Medicine, Baltimore, Maryland.
Int J Womens Dermatol. 2021 Jun 25;7(5Part B):692-696. doi: 10.1016/j.ijwd.2021.06.005. eCollection 2021 Dec.
Although primary cutaneous melanoma accounts for approximately 3% of all malignant skin tumors, it has the greatest contribution to skin cancer-related death. Sex-specific differences in melanoma tumor behavior have been described, and melanoma pathogenesis may be hormonally mediated. This review aims to summarize the literature to date regarding the effects of hormone therapy on melanoma in women. Women's exogenous hormone use has changed dramatically over the past few decades. Thus, we focus on studies investigating the associations between oral contraception, fertility treatments, menopausal hormone therapy (MHT), and melanoma. Across hormone therapy types, there does not appear to be a well-established association between exogenous female hormones and melanoma incidence. However, MHT practices and formulations vary significantly across countries. Although MHT does not appear to increase melanoma risk in studies from the United States, conflicting results have been observed in Europe. Unopposed estrogen MHT formulations require further investigation to determine a clear pattern between hormone use and the development of melanoma.
尽管原发性皮肤黑色素瘤约占所有恶性皮肤肿瘤的3%，但其对皮肤癌相关死亡的贡献最大。黑色素瘤肿瘤行为存在性别差异，黑色素瘤的发病机制可能由激素介导。本综述旨在总结迄今为止关于激素治疗对女性黑色素瘤影响的文献。在过去几十年中，女性外源性激素的使用发生了巨大变化。因此，我们重点关注研究口服避孕药、生育治疗、绝经激素治疗（MHT）与黑色素瘤之间关联的研究。在各种激素治疗类型中，外源性女性激素与黑色素瘤发病率之间似乎没有明确的关联。然而，不同国家的MHT实践和配方差异很大。尽管在美国的研究中MHT似乎不会增加黑色素瘤风险，但在欧洲观察到了相互矛盾的结果。单纯雌激素MHT配方需要进一步研究，以确定激素使用与黑色素瘤发生之间的明确模式。
